Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: A case-control study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Van der Watt, Johan J ^a   Wilkinson, Katalin A ^a,b   Wilkinson, Robert J ^a,b,c   Heckmann, Jeannine M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretroviral toxicity; Cytokines; HIV neuropathy; Immune reconstitution; Interleukin 1 receptor antagonist; Neuropathic symptoms; Sensory neuropathy

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; BLOOD; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGY; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; YOUNG ADULT;

ADULT; ANTI-RETROVIRAL AGENTS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CYTOKINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; YOUNG ADULT;

EID: 84893661055     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-71     Document Type: Article

References (45)

1. Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, Levitt NS, Heckmann JM. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve 2010, 41:599-606.
2. Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, Gelman BB, Vaida F, Collier A, Marra CM, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 2010, 67:552-558. 10.1001/archneurol.2010.76, 3924778, 20457954.
3. Arenas-Pinto A, Bhaskaran K, Dunn D, Weller IV. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial. Antivir Ther 2008, 13:289-295.
4. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Safety 1998, 19:481-494. 10.2165/00002018-199819060-00005, 9880091.
5. Centner CM, Bateman KJ, Heckmann JM. Manifestations of HIV infection in the peripheral nervous system. Lancet Neurol 2013, 12:295-309. 10.1016/S1474-4422(13)70002-4, 23415569.
6. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003, 2:812-822. 10.1038/nrd1201, 14526384.
7. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 2001, 81:1537-1544. 10.1038/labinvest.3780367, 11706061.
8. Cote HC. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy. Antivir Ther 2005, 10(Suppl 2):M3-M11.
9. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, Holmberg SD. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003, 32:48-56. 10.1097/00126334-200301010-00007, 12514413.
10. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004, 38:e79-e80. 10.1086/383151, 15095236.
11. Currier JS. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis 2007, 45:261-262. 10.1086/518977, 17578789.
12. Bonnet F, Bonarek M, Morlat P, Mercie P, Dupon M, Gemain MC, Malvy D, Bernard N, Pellegrin JL, Beylot J. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis 2003, 36:1324-1328. 10.1086/374601, 12746780.
13. Kleinschnitz C, Brinkhoff J, Zelenka M, Sommer C, Stoll G. The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol 2004, 149:77-83. 10.1016/j.jneuroim.2003.12.013, 15020067.
14. Taskinen HS, Olsson T, Bucht A, Khademi M, Svelander L, Roytta M. Peripheral nerve injury induces endoneurial expression of IFN-gamma, IL-10 and TNF-alpha mRNA. J Neuroimmunol 2000, 102:17-25. 10.1016/S0165-5728(99)00154-X, 10626662.
15. Zelenka M, Schafers M, Sommer C. Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain 2005, 116:257-263. 10.1016/j.pain.2005.04.018, 15964142.
16. Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain 1998, 74:35-42. 10.1016/S0304-3959(97)00148-6, 9514558.
17. Uceyler N, Rogausch JP, Toyka KV, Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology 2007, 69:42-49. 10.1212/01.wnl.0000265062.92340.a5, 17606879.
18. Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, McClernon DR, Conant K, Cohen B, Epstein LG, Kieburtz K. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005, 64:842-848. 10.1212/01.WNL.0000152981.32057.BB, 15753420.
19. Cherry CL, Rosenow A, Affandi JS, McArthur JC, Wesselingh SL, Price P. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk. AIDS Res Hum Retroviruses 2008, 24:117-123. 10.1089/aid.2007.0168, 18240960.
20. Tyor WR, Wesselingh SL, Griffin JW, McArthur JC, Griffin DE. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:379-388.
21. Chew CS, Cherry CL, Kamarulzaman A, Yien TH, Aghafar Z, Price P. A longitudinal study of the effects of ART on plasma chemokine levels in Malaysian HIV patients. Dis Markers 2011, 31:303-309. 10.1155/2011/714057, 3826423, 22048272.
22. Wilkinson KA, Seldon R, Meintjes G, Rangaka MX, Hanekom WA, Maartens G, Wilkinson RJ. Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 2009, 180:674-683. 10.1164/rccm.200904-0568OC, 19628776.
23. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M, Ie DEAS, Central A. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:251-261. 10.1016/S1473-3099(10)70026-8, 20334848.
24. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523. 10.1016/S1473-3099(08)70184-1, 2804035, 18652998.
25. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med 2009, 30:797-810. 10.1016/j.ccm.2009.08.013, 19925968.
26. Tadokera R, Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Seldon R, Chegou NN, Maartens G, Rangaka MX, Rebe K, et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Resp J 2011, 37:1248-1259.
27. Morgello S, Estanislao L, Simpson D, Geraci A, DiRocco A, Gerits P, Ryan E, Yakoushina T, Khan S, Mahboob R, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004, 61:546-551. 10.1001/archneur.61.4.546, 15096404.
28. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD, Investigators HIVOS Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005, 40:148-157. 10.1086/426076, 15614705, Investigators HIVOS.
29. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Ann Rev Immunol 1998, 16:27-55.
30. Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis 2002, 185:971-979. 10.1086/339408, 11920322.
31. Cox SE, Arthur P, Kirkwood BR, Yeboah-Antwi K, Riley EM. Vitamin A supplementation increases ratios of proinflammatory to anti-inflammatory cytokine responses in pregnancy and lactation. Clin Exp Immunol 2006, 144:392-400. 10.1111/j.1365-2249.2006.03082.x, 1941972, 16734607.
32. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996, 39:379-385. 10.1002/art.1780390305, 8607886.
33. Sacktor N, Nakasujja N, Skolasky RL, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009, 72:165-170. 10.1212/01.wnl.0000339042.96109.86, 2677497, 19139369.
34. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989, 7:145-173.
35. Chikanza IC, Roux-Lombard P, Dayer JM, Panayi GS. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 1993, 92:19-22. 1554888, 8385584.
36. Barnes A. Measurement of serum cytokines. Lancet 1998, 352:324-325.
37. Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011, 11:40. 10.1186/1471-2334-11-40, 3042932, 21294867.
38. Conesa-Botella A, Meintjes G, Coussens AK, van der Plas H, Goliath R, Schutz C, Moreno-Reyes R, Mehta M, Martineau AR, Wilkinson RJ, et al. Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. Clin Infect Dis 2012, 55:1004-1011. 10.1093/cid/cis577, 3436923, 22715179.
39. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000, 191:303-312. 10.1084/jem.191.2.303, 2195758, 10637274.
40. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
41. Thea DM, Porat R, Nagimbi K, Baangi M, St Louis ME, Kaplan G, Dinarello CA, Keusch GT. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1. Ann Intern Med 1996, 124:757-762. 10.7326/0003-4819-124-8-199604150-00009, 8633837.
42. Jones G, Zhu Y, Silva C, Tsutsui S, Pardo CA, Keppler OT, McArthur JC, Power C. Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology 2005, 334:178-193. 10.1016/j.virol.2005.01.027, 15780868.
43. Acharjee S, Zhu Y, Maingat F, Pardo C, Ballanyi K, Hollenberg MD, Power C. Proteinase-activated receptor-1 mediates dorsal root ganglion neuronal degeneration in HIV/AIDS. Brain 2011, 134:3209-3221. 10.1093/brain/awr242, 3212716, 22021895.
44. Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, Cirino G, Gerard N, Basbaum AI, Andrade-Gordon P, et al. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nature medicine 2001, 7:821-826. 10.1038/89945, 11433347.
45. Alier KA, Endicott JA, Stemkowski PL, Cenac N, Cellars L, Chapman K, Andrade-Gordon P, Vergnolle N, Smith PA. Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons. J Pharmacol Exp Ther 2008, 324:224-233.